Citation & Authors
Clin J Am Soc Nephrol. 2026;.
ABSTRACT · RESEARCH SUMMARY
Research summary
This target trial emulation matched 2,045 patients per group. Romosozumab was associated with fewer vertebral fractures at 12 months (HR 0.64; 95% CI 0.42–0.98), with no significant differences in nonvertebral or hip fractures. Major cardiovascular events were also less frequent (0.82; 0.70–0.97). This observational finding requires prospective validation and does not replace existing cardiovascular safety precautions.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
